



# Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study

Kyunghwan Oh<sup>1\*</sup>, Hee Seung Hong<sup>1\*</sup>, Nam Seok Ham<sup>1§</sup>, Jungbok Lee<sup>2</sup>, Sang Hyoung Park<sup>1,3,4</sup>, Suk-Kyun Yang<sup>1,3,4</sup>, Hyuk Yoon<sup>5</sup>, You Sun Kim<sup>6</sup>, Chang Hwan Choi<sup>7</sup>, Byong Duk Ye<sup>1,3,4</sup>, on behalf of the Korean Association for the Study of Intestinal Diseases

*Departments of<sup>1</sup>Gastroenterology and<sup>2</sup>Clinical Epidemiology and Biostatistics, <sup>3</sup>Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul; <sup>4</sup>Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul; <sup>5</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam; <sup>6</sup>Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul; <sup>7</sup>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea*

<https://doi.org/10.5217/ir.2021.00173>  
Intest Res 2023;21(1):137-147

In the article entitled "Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study,"<sup>1</sup> the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.

"Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/**29 (59.2%)** patients at week 8 and **26 (53.1%)**/34 (69.4%) patients at week 20, respectively (Fig. 2)."

## REFERENCE

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study. Intest Res 2023;21:137-147.